跳转至内容
Merck
CN

主要文件

查看所有文档

A5602

AMD3100 八盐酸盐 水合物

≥97% (NMR), solid, CXCR4 antagonist

别名:

1,1′-[1,4-亚苯基双（亚甲基）]双-1,4,8,11-四氮杂 八盐酸盐, JM3100, SID791, 普乐沙福

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:
C28H54N8 · 8HCl · xH2O
化学文摘社编号:
155148-31-5
分子量:
794.47 (anhydrous basis)
MDL number:
MFCD29072959
UNSPSC Code:
51111800
PubChem Substance ID:
24724394
NACRES:
NA.77
Assay:
≥97% (NMR)
Form:
solid
Quality level:
100
Storage condition:
desiccated
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

AMD3100 八盐酸盐 水合物, ≥97% (NMR), solid

Quality Level

100

assay

≥97% (NMR)

form

solid

storage condition

desiccated

solubility

H2O: ≥10 mg/mL, clear

originator

Sanofi Aventis

storage temp.

−20°C

SMILES string

Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].[H]O[H].C1CNCCNCCCN(CCNC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2

InChI

1S/C28H54N8.8ClH.H2O/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36;;;;;;;;;/h5-8,29-34H,1-4,9-26H2;8*1H;1H2

InChI key

GKFHDCZYJHUPEN-UHFFFAOYSA-N

Application

AMD3100是一种高度特异性的趋化因子受体CXCR4的拮抗剂。 AMD3100已被用于一项研究，以确定其对口腔鳞状细胞癌中CXCR4的阻断和对淋巴结转移的抑制。

Biochem/physiol Actions

AMD3100是一种高度特异性的趋化因子受体CXCR4的拮抗剂。

Features and Benefits

该化合物是由 Sanofi Aventis开发。浏览其他医药开发的化合物和已批准的药物/候选药物清单，请点击这里。

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
056M4602V
115M4607V
053M4615V
012M4618V
090M4614

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Christine Feig et al.
Proceedings of the National Academy of Sciences of the United States of America, 110(50), 20212-20217 (2013-11-28)
An autochthonous model of pancreatic ductal adenocarcinoma (PDA) permitted the analysis of why immunotherapy is ineffective in this human disease. Despite finding that PDA-bearing mice had cancer cell-specific CD8(+) T cells, the mice, like human patients with PDA, did not
David H McDermott et al.
Blood, 123(15), 2308-2316 (2014-02-14)
Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare immunodeficiency disorder caused by gain-of-function mutations in the G protein-coupled chemokine receptor CXCR4. The CXCR4 antagonist plerixafor, which is approved by the US Food and Drug Administration (FDA) for stem
Brian A Zabel et al.
Molecular cancer, 10, 73-73 (2011-06-16)
Migration of metastatic tumor cells from the bloodstream into lymph nodes is thought to be facilitated by expression of the chemokine receptors CCR7, CXCR4 and, for B cell-derived tumors, CXCR5. Expression of their respective chemokine ligands (CCL19, CCL21, CXCL12 and
查看所有相关文献

全球贸易项目编号

货号GTIN
A5602-5MG04061833376096